Test Your Hypothesis

 BGPT Odds of True

FDX1-lipoylation-gated cuproptosis is well supported, but the specific COF-Tpy-Se-Cu material, oncolytic adenovirus scheduling, and radiation-fraction dependence have zero direct evidence in the supplied records; plausibility is mechanistic only.

 Hypothesis Novelty

Combining covalent-organic-framework copper delivery, oncolytic adenovirus fraction timing, and FDX1-mediated cuproptosis is a novel, untested triad; only the cuproptosis core is established.

 Quick Analysis Plan Copied

 Long Analysis Plan

What the evidence actually supports

Deep mutational scanning of human FDX1 (3,740 variants across 183 residues in ABC1 and HEK293T cells) identified D136 and D139 on α-helix 3 as critical for both cuproptosis sensitivity and DLAT lipoylation; charge-reversal mutants (D136R/D139R) abolish cellular function while retaining in vitro enzymatic activity, implicating an electrostatic partner interface — with DLD emerging as the likely upstream reductase over FDXR FDX1 deep mutational scanning.

FDX1 levels are not static: in gastric cancer, copper stress lactylates METTL16 at K229, increasing m6A modification of FDX1 mRNA (METTL16-FDX1 mRNA correlation r=0.5084, TMA r=0.4662, both p<0.0001; SIRT2-FDX1 correlation r=-0.4536, p=0.0062), and elesclomol+AGK2 suppressed xenograft volume (p=0.0013) and weight (p=0.00027) METTL16 lactylation controls FDX1 and cuproptosis. FDX1-dependent cuproptosis is anchored to the lipoylation pathway (LIAS, LIPT1, DLAT, DLD, PDHA1/PDHB) and is selectively lethal in high-mitochondrial-metabolism tumors Cuproptosis mechanisms review.

What is missing for the hypothesis

No supplied source involves COF-Tpy-Se-Cu, oncolytic adenovirus, or radiation-fraction scheduling. The hypothesis therefore stacks three unevidenced premises onto an evidenced core (FDX1-lipoylation-cuproptosis axis). Key unknowns: whether the COF delivers bioavailable Cu and preserves the FDX1-D136/D139 interface; whether adenoviral infection or radiation shifts METTL16/SIRT2 balance or DLD activity (both plausibly radiation- and redox-sensitive, but untested here); and whether fraction spacing changes intracellular Cu flux faster than FDX1 protein turnover. Counterfactual risk: FDX1-independent copper death and pan-cancer context-dependence (FDX1 is prognostic in opposite directions across cancers, e.g., HR=2.2 in ACC vs HR=0.56 in KIRC) undermine any universal prediction FDX1 pan-cancer in-silico analysis.

Disproof test: if radioresistant tumors treated with COF-Tpy-Se-Cu + radiation show identical FDX1 stabilization and DLAT oligomerization regardless of virus-before vs virus-after fraction timing, the scheduling hypothesis is falsified and the effect, if any, is dose- rather than sequence-determined.